Zepbound vs Wegovy: Which Is Cheaper Depends on Who Is Buying

Ask which of the two big weight-loss injections is cheaper and you will get an answer that depends entirely on which door you walked through. Buy direct from the manufacturer and Zepbound® is the more expensive one. Look at what a retail pharmacy pays to put the same box on its shelf and Wegovy® is the more expensive one, by a wide margin. Both numbers are published. They point opposite ways.

The cash prices, as the manufacturers print them

Eli Lilly sells Zepbound to self-pay patients through LillyDirect at three tiers, and the KwikPen and the single-dose vial cost exactly the same at each tier: $299/month at 2.5 mg, $399 at 5 mg, and $449 at 7.5, 10, 12.5 and 15 mg.¹ A month there is defined as 28 days.

Novo Nordisk sells Wegovy to self-pay patients through NovoCare Pharmacy at $349/month for the 0.25, 0.5, 1, 1.7 and 2.4 mg pens, with the high-dose 7.2 mg pen at $399. New patients pay $199/month for their first two fills, an offer Novo's own price guide says runs through 31 December 2026.² A month there is one box of four pens — also 28 days.

So at steady state, on the manufacturer's own cash channel: $449 against $349. Zepbound costs $100 a month more.

A first year, with the arithmetic shown

Twenty-eight-day months mean 13 fills in 365 days, not 12. That single fact moves an annual figure by hundreds of dollars, so both years below are priced at 13.

Zepbound, escalating one step per fill — the fastest the label's schedule allows, since it calls for 2.5 mg for four weeks and increases of 2.5 mg after at least four weeks³ — and settling at 10 mg: $299 + $399 + $449 + (10 × $449) = $5,637.

Wegovy, taking the two new-patient fills and then the standard rate: (2 × $199) + (11 × $349) = $4,237.

Difference in year one: $1,400. In year two, with no introductory pricing on either side, it is 13 × $449 against 13 × $349 — $5,837 against $4,537, or $1,300.

Now flip the channel

CMS publishes NADAC, a survey of what retail pharmacies actually pay their wholesalers, per millilitre or per tablet. It is not a list price and it is not a patient price. It is the closest thing there is to a neutral read on what these products cost to buy in bulk.

On the file dated 5 August 2026, with rates effective 22 July 2026⁴:

Wegovy 2.4 mg pen — $435.57294 per mL × 0.75 mL × 4 pens = $1,306.72 for a month's box.

Zepbound 10 mg single-dose pen — $526.15096 per mL × 0.5 mL × 4 pens = $1,052.30 for a month's box.

Zepbound KwikPen, 10 mg per dose — $281.30588 per mL × 2.4 mL = $675.13 for the same four doses in one multi-dose device.

Read those three lines together. The drug that costs you $100 more a month in cash costs a pharmacy $254 less a month to acquire in its single-dose form, and $632 less in its KwikPen form. Whichever answer you have heard to "which is cheaper", it was answered from one channel only.

Why a $449 cash price can sit below acquisition cost

The $449 Lilly charges a self-pay patient for a 10 mg KwikPen is $226 below the $675 a retail pharmacy pays for the same device. That is not a subsidy conjured from nothing — it is what a manufacturer can do when it sells to you directly and no wholesaler, dispensing pharmacy or pharmacy benefit manager takes a margin in between. The same logic runs on the Novo side: $349 against a $1,306.72 acquisition cost.

The practical consequence is the one nobody likes: on these two drugs, the direct cash channel is frequently cheaper than running a claim through a plan that leaves you with coinsurance. Which is not a recommendation — it is a reason to price both before choosing.

They are not approved for the same things, and that decides it for some readers

Zepbound's label carries two indications: chronic weight management in adults with obesity or overweight with a weight-related comorbid condition, and moderate-to-severe obstructive sleep apnoea in adults with obesity.³

Wegovy's injection label carries three: cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight; weight reduction in adults and in patients aged 12 and over with obesity; and, under accelerated approval, non-cirrhotic MASH with moderate-to-advanced fibrosis.⁵

If your prescription exists because of sleep apnoea, there is no Wegovy price to compare against. If it exists because of MASH or an established cardiovascular indication, there is no Zepbound price to compare against. A price comparison between two drugs a given reader cannot substitute is decoration.

What insurance does to all of it

Both manufacturers publish a commercial-insurance figure alongside the cash one, and they are structured differently.

Novo's Wegovy copay offer is "pay as little as $25", explicitly capped at a maximum saving of $100 a month, with government beneficiaries excluded.² A $100 ceiling means the offer can only carry you $100 of the way; what you pay is your plan's number minus up to $100.

Lilly's Zepbound savings card starts at $25 for up to a three-month prescription when the plan covers the drug, and its terms state the card expires and savings end on 31 December 2026.⁶

Both are dated instruments. Neither is a price.

What we could not establish

We could not price a year of either drug through a specific insurance plan, because neither manufacturer publishes plan-level cost sharing and no public source lists it per drug. We could not verify a Zepbound single-dose-vial NADAC line, because none appears in the 5 August 2026 file under that description. And the Wegovy HD 7.2 mg NADAC figure we found carries an effective date of 17 June 2026 rather than 22 July, so it is not strictly comparable with the rows above and we have left it out of the arithmetic.

For the sellers who resell these two drugs with a membership stacked on top, see our Ro review and Hers review — and for the compounded alternative, compounded tirzepatide vs branded Zepbound.

Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Doseworth is not affiliated with either.